Individualized Answers For Patients With Breast Cancer
EndoPredict® provides accurate results for patients diagnosed with ER+, HER2−, early-stage breast cancer with either node-negative or node-positive disease (1- 3 nodes). The test combines a 12-gene molecular score (tumor biology) with tumor size and nodal status (tumor pathology) to significantly improve prognostic performance over the leading competitor.
EndoPredict provides an individualized early and late recurrence result for each patient based on their tumor’s biology and pathology. With the integration of these specific features, EndoPredict also accurately predicts an individualized absolute chemotherapy benefit to help you make the right treatment decisions for each individual case of breast cancer.
EndoPredict provides an individualized early and late recurrence result for each patient based on their tumor’s biology and pathology. With the integration of these specific features, EndoPredict also accurately predicts an individualized absolute chemotherapy benefit to help you make the right treatment decisions for each individual case of breast cancer.
Your patients, their questions
Answering Critical Questions About Breast Cancer
- What is the risk of the cancer returning within 10 years?
- Is there a benefit to treating with chemotherapy?
- Is there enough benefit to treat with extended endocrine therapy?
Let us help you find the right answers.
Patients
I am a patient or a caregiver looking for answers that will help guide cancer treatment decisions and provide peace of mind for me.
Providers
I am a physician looking to find critical answers about my patients’ cancer to provide peace of mind.
